The AIM-PD trial (ambroxol)

Supported by Cure Parkinson’s, Van Andel Institute and the John Black Foundation, the next phase of this trial programme will follow shortly. Phase 2 of the ‘AIM-PD’ study was a proof of concept study and involved 20 people with the genetic form of Parkinson’s over a 24…


Clinical trials

The UP-Study trial (UDCA)

  This trial is now complete. Supported by Cure Parkinson’s and the J P Moulton Foundation, the results are expected in 2021. Originally used to treat cirrhosis of the liver, researchers found that the rescue effect of UDCA on the liver cells may actually be due…


News Clinical trials

The PD-STAT/Simvastatin study results

Why is this important? In 2012, an international committee of Parkinson’s experts brought together by Cure Parkinson’s prioritised simvastatin for clinical evaluation in Parkinson’s. The International Linked Clinical Trials (iLCT) committee believed that there was considerable supporting evidence indicating that this widely used medication may…


News Clinical trials

An overview of drug development for Parkinson’s

A recently published research report conducted by Parkinson’s research advocates and Cure Parkinson’s presents an encouraging overview of pipeline agents being clinically tested for Parkinson’s.


Ambroxol in Parkinson’s: results of phase 2 trial published

Cure Parkinson’s, in partnership with Van Andel Institute and the John Black Charitable Foundation, is proud to announce the publication of the results of the phase 2 clinical trial that evaluated the safety and tolerability of ambroxol to treat Parkinson’s. The trial background In late…